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Table. High-sensitivity C-reactive protein (hsCRP), B-type natriuretic
peptide (BNP), and other predictors of major adverse limb events
(MALE) and major adverse cardiovascular events (MACE)
HR (95% CI) P value
MALE at 2 years
Overall cohort
hsCRP 1.1 (1.0-1.2) .059
Male gender 1.6 (1.0-2.6) .062
Chronic limb ischemia 1.8 (1.1-3.1) .020
Outﬂow procedure 1.8 (1.1-3.2) .033
Procedure speciﬁc model
Endovascular
hsCRP 1.2 (1.0-1.4) .016
Outﬂow procedure 2.7 (1.4-5.2) .004
Obesity (BMI >30) 2.5 (1.3-4.8) .006
Open surgical
Male gender 3.4 (1.5 -7.8) .003
Hyperlipidemia 2.4 (1.2-5.1) .016
Vein bypass conduit (vs prosthetic) 3.5 (1.6-7.6) .002
MACE at 2 years
Overall cohort
BNP 1.02 (1.0-1.04) .018
Coronary artery disease 2.2 (0.9-5.4) .075
Procedure speciﬁc model
Endovascular
Age 1.05 (1.00-1.09) .033
Heart failure 10.6 (2.0-56.9) .006
Open surgical
BNP 1.03 (1.01-1.04) .003
BMI, Body mass index; CI, conﬁdence interval; HR, hazard ratio; MI,
myocardial infarction.
We used Cox proportional-hazards models to assess univariate and multivar-
iable covariates. HRs and 95% CI were calculated for each factor by univariate
analysis. All prognostic factors with P < .10 were included into a Cox multi-
variate analysis with back-wards entry to determine independent predictors.
JOURNAL OF VASCULAR SURGERY
1722 Abstracts December 2014models were applied to risk-stratify patients. b-Blocker (BB) status of none
vs acute (0-30 days preoperatively) vs chronic (>30 days preoperatively) was
evaluated, and a Bonferroni correction with a P < .002 was used to declare
any result signiﬁcant at a 5% error rate. Logistic regression generalized esti-
mating equations and linear mixed models were used with MACE as the
outcome, and AHR/HRC, BB status, and the interaction between
AHR/HRC and BB status as ﬁxed factors.
Results: A total of 13,141 elective patients were reviewed (IIB: n¼ 8155
[62%];SIB:n¼2629[18%];oAAA:n¼2629[20%]).The rawnonrisk adjusted
rates of MACE and 30-day mortality were IIB: MACE, 9.8% (n ¼ 633) and
2.0% (n ¼ 126); SIB, 15.7% (n ¼ 263) and 2.6% (n ¼ 43); and oAAA, 21.7%
(n ¼ 486) and 3.3% (n ¼ 73). Rates of any preoperative BB exposure were
IIB, 66.5% (n ¼ 5412); SIB, 57% (n ¼ 1342); and oAAA, 74.2% (n ¼ 1949).
Association of AHR and HRC with outcomes was variable across patients and
procedures. AHR of <75 beats/min was associated with increased risk of
POMI for IIB patients across all cardiac risk strata (odds ratio [OR], 1.4; 95%
conﬁdence interval [CI], 1.03-1.9; P ¼ .03), whereas AHR >75 beats/min
was associated with increased risk for dysrhythmia (OR, 2.4; 95% CI, 1.6-3.6;
P ¼ .0001) and 30-day death (OR, 2.0; 95% CI, 1.3-3; P ¼ .001) in moder-
ate-risk and high-cardiac-risk patients. TheseHReffects disappearedwhen con-
trolling for BB status. SIB had no association between AHR and 30-day
mortality; however, AHR >75 beats/min was associated with an increased
risk of congestive heart failure congestive heart failure across all cardiac risk strata
(OR, 2.2; 95%CI, 1.2-3.8;P¼ .007). These effects also disappearedwhen con-
trolling for BB exposure. No association with HR and MACE outcome was
noted amongoAAApatients irrespectiveofBB status.However, 30-daymortal-
ity was increased (OR, 1.9; 95% CI, 1.03-3.4; P ¼ .04) for patients with AHR
>75 beats/min. This association was sustained when controlling for acute but
not chronic BB status. HRC was analyzed among all three operations, and
inconsistent associations with MACE or 30-day mortality were detected.
Conclusions: HRishighly confoundedbypatientpresentation,operative
variables, andBBtherapy.Thediscordancebetweencardiac risk andHRaswell as
the lack of consistent correlation to outcome makes this an unreliable predictor.
TheVQIhas elected to discontinue collectingheart rate data nationally given the
lack of sufﬁcient data to suggest its importance as an outcome measure.
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Introduction: Previously, our group reported on the preoperative
markers, high-sensitivity C-reactive protein (hsCRP), and B-type natriuretic
peptide (BNP) and their ability to predict future major adverse limb events
(MALE) and major adverse cardiovascular events (MACE) after lower ex-
tremity endovascular interventions. Others have reported the predictive po-
wer of these biomarkers for adverse outcomes in endovascular cohorts or
open surgical reconstructions. No literature currently addresses the use of
these biomarkers while comparing revascularization strategies or while
examining autologous and prosthetic reconstructions in surgical bypasses.
Methods: We retrospectively examined patients who underwent elec-
tive endovascular intervention or open surgical reconstruction for lower ex-
tremity peripheral arterial occlusive disease between January 1, 2007, and
December 31, 2013. All procedures were performed by a single operator. Pa-
tients’ preprocedural levels of hsCRP and BNP were measured, and they un-
derwent postprocedural ankle-brachial index measurement and duplex
ultrasound imaging or contrast angiography. Examined outcomes included
MALE (composite end point of target vessel revascularization, limb amputa-
tion, or disease progression) and MACE (stroke, myocardial infarction, or
death) occurring by 24 months. The relationship between baseline hsCRP
and BNP levels and time to the MALE and MACE was examined by univar-
iate and multivariate Cox proportional hazard regression analyses.
Results: The analysis included 245 limbs in 200 patients (median age
[interquartile range], 63 [53-71] years), with 156 limbs receiving endovas-
cular revascularization and 89 limbs receiving surgical reconstruction. The
surgical cohort was composed of a greater proportion of: men (62% vs
42%; P ¼ .01), limbs with critical limb ischemia (60% vs 17%; P < .01),
and outﬂow procedures (82% vs 39%; P < .01) compared with the endovas-
cular cohort. Preprocedural levels of hsCRP and BNP did not differ be-
tween surgically and endovascularly treated limbs (hsCRP, 0.57 [0.26-
1.18] vs 0.43 [0.22-0.96] mg/dL; P ¼ .21; BNP, 43 [18-112] vs 44
[18-82] pg/mL; P ¼ .66). When endovascularly treated limbs wereexamined in isolation, multivariate analysis demonstrated that higher hsCRP
levels were signiﬁcantly associated with MALE (hazard ratio [HR], 1.2; 95%
conﬁdence interval [CI] 1.0-1.4; P ¼ .02; Table). In surgical reconstruc-
tions, neither BNP nor hsCRP was associated with MALE; however, the
use of a vein bypass conduit (vs prosthetic reconstruction) signiﬁcantly pred-
icated MALE (HR, 3.5; 95% CI, 1.6-7.6; P < .01). HsCRP failed to asso-
ciated with MACE in endovascularly or surgically treated limbs. However,
elevated BNP levels associated with MACE in the surgical cohort (HR,
1.03; 95% CI, 1.01-1.04; P < .01) but not in those receiving endovascular
intervention.
Conclusions: Elevated hsCRP levels predicted inferior results in
endovascular reconstructions, whereas elevated BNP levels associated with
impaired long-term survival in patients with surgical revascularizations.
Additional studies should use biochemical markers to further stratify out-
comes after both types of vascular interventions as a means to elucidate
how biomarkers can best assist clinical decision-making for outcome
improvement.
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Introduction: An iCAST covered balloon-expandable stent (Maquet
Getinge Group, Hudson, NH) has been used in the superior mesenteric ar-
tery (SMA) to treat a variety of pathology and most recently for visceral
stenting in fenestrated endovascular aortic repair (FEVAR). Stenting has
primarily been investigated by bench studies involving ﬁnite element analysis
in the coronaries; however, further explanation of the mechanical behavior
has not been performed. This study examined Atrium stent expansion using
a pseudoballoon and then a second simulation expanding the stent into a
theoretical SMA.
